Potential SpaceX IPO Could Join Historys Largest Stock Market Debuts SGX RegCo Gives Suspended Firms Three Years to Resume Trading or Face Delisting FC Barcelona Confirms Departure of Star Player Alexia Putellas After 14 Seasons UK VAT Cut for Theme Parks and Childrens Meals Potential Boost for Summer Tourism Nvidia May Spend Up to 150 Billion Annually on Taiwan AI Suppliers Jensen Huang Reveals US Travel Association Releases Travel Price Index for May 2026 German American Bancorp Inc GABC Q1 2026 Earnings EPS Misses Estimates Stock Declines on Headwinds ABVX Q4 2025 Earnings WiderThanExpected Loss Highlights ClinicalStage Biotech Challenges FirstService Q1 2026 Earnings EPS Beats Estimates Stock Slips Slightly Mistras Group Inc MG Q1 2026 Earnings EPS Surges Past Estimates with 55 Surprise MTNB Q4 2024 Earnings NarrowerthanExpected Loss Drives Positive Stock Movement EVER Q1 2026 Earnings Strong EPS Beat Drives Positive Market Reaction First Trust Preferred Income Fund FPF Edges Higher Amid Steady Income Appeal Endava DAVA Faces Continued Pressure as Shares Slide Over 1 QC Technologies Inc QCLS Surges 199 Key Levels and Technical Outlook HWH International Inc HWH Consolidates Near 110 as Trading Remains Muted BIOX Edges Higher as Shares Test Resistance in Narrow Range Lockheed Martin Stock Gains as USIran Tensions Escalate Contineum Therapeutics Inc CTNM Q1 2026 Earnings Narrower Loss Beats Expectations Social Commerce Partners Unit SCPQU Edges Higher SPAC Unit Tests Key Resistance Near 1074 ACTG Q1 2026 Earnings EPS Misses Estimates by Wide Margin as Revenue Unreported TAC Q1 2026 Earnings EPS Misses Estimates but Stock Rises on Operational Momentum FCX Q1 2026 Earnings EPS Surpasses Estimates by 23 Stock Declines Slightly Catheter Precision Inc Q1 2025 Earnings EPS Misses Estimates by Wide Margin Stock Rises Despite Deep Loss Tidewater Q1 2026 Earnings EPS Misses Estimates by Wide Margin Stock Declines KKRT Q1 2026 Earnings EPS Surprise Positive Despite Slight Stock Decline ASND Q1 2026 Earnings Wide EPS Miss as Ascendis Pharma Remains PreRevenue Stock Edges Higher